Zacks: Analysts Expect Advaxis (ADXS) Will Announce Earnings of -$0.41 Per Share

Analysts forecast that Advaxis (NASDAQ:ADXS) will announce earnings per share (EPS) of ($0.41) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Advaxis’ earnings, with estimates ranging from ($0.42) to ($0.39). Advaxis posted earnings of ($0.51) per share during the same quarter last year, which suggests a positive year over year growth rate of 19.6%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, June 5th.

According to Zacks, analysts expect that Advaxis will report full year earnings of ($1.73) per share for the current financial year, with EPS estimates ranging from ($1.91) to ($1.50). For the next financial year, analysts forecast that the firm will post earnings of ($1.48) per share, with EPS estimates ranging from ($1.96) to ($1.08). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Advaxis.

Advaxis (NASDAQ:ADXS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.49) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. The firm had revenue of $2.06 million during the quarter, compared to the consensus estimate of $3.03 million. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%.

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Advaxis in a report on Tuesday, April 17th. Cantor Fitzgerald decreased their price target on Advaxis from $19.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, March 13th. Finally, ValuEngine upgraded Advaxis from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

A number of institutional investors have recently made changes to their positions in ADXS. Wells Fargo & Company MN grew its holdings in Advaxis by 39.9% during the fourth quarter. Wells Fargo & Company MN now owns 66,206 shares of the biotechnology company’s stock worth $187,000 after buying an additional 18,892 shares in the last quarter. Cutler Capital Management LLC grew its holdings in Advaxis by 51.8% during the fourth quarter. Cutler Capital Management LLC now owns 75,876 shares of the biotechnology company’s stock worth $215,000 after buying an additional 25,876 shares in the last quarter. Franklin Street Advisors Inc. NC grew its holdings in Advaxis by 117.1% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 129,800 shares of the biotechnology company’s stock worth $369,000 after buying an additional 70,000 shares in the last quarter. Bank of Montreal Can grew its holdings in Advaxis by 16,465.9% during the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock worth $1,230,000 after buying an additional 430,583 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Advaxis by 1,200.1% during the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock worth $1,326,000 after buying an additional 431,379 shares in the last quarter. Institutional investors and hedge funds own 28.28% of the company’s stock.

Shares of Advaxis traded up $0.14, hitting $1.78, during midday trading on Friday, according to Marketbeat. 1,151,092 shares of the stock traded hands, compared to its average volume of 394,774. Advaxis has a one year low of $1.64 and a one year high of $1.87. The company has a market cap of $89.46 million, a price-to-earnings ratio of -0.77 and a beta of 1.25.

Advaxis Company Profile

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Get a free copy of the Zacks research report on Advaxis (ADXS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply